News Coverage

UbiVac Opts to Stay in Portland, Oregon, Expands Lab Space By Factor of 10

First few lines of the story — Portland, Ore.-based UbiVac, after considering moving to San Francisco or San Diego, has chosen to remain in Portland and move into a larger site.

UbiVac focuses on immuno-oncology. Its lead product is DPV-001 (DRibble), a first-in-class dendritic cell (DC)-targeted…, February 18, 2016

Hot Portland biotech finds suitable lab space at 11th hour to avoid leaving city

Having outgrown its space at Providence Cancer Center, UbiVac’s leaders were evaluating other options, including a possible move to San Diego or the San Francisco Bay Area.

Portland Business Journal,  Health Care Inc. Northwest, February 17, 2016

UbiVac seeks partnership or Series A by early 2016, engages CRO CRAB for NSCLC trial – CEO

UbiVac is in active discussions with potential partners and hopes to have at least one collaborative partnership in place by early 2016 for its vaccine DPV001, said CEO Bernard Fox …

BIOPHARM INSIGHT, October 7, 2015

Providence Cancer spinoff inks agreement with major pharma company

The vaccine, called DPV-001, stimulates a patient’s own immune system in the fight against invading tumors. It’s designed for patients who have gone through other treatment…

Portland Business Journal, September 11, 2015

Providence will test its new lung cancer vaccine at Mayo, other top clinics

Providence Cancer Center has embarked on a new lung cancer vaccine trial encompassing multiple sites around the country, including the Mayo Clinic.

Portland Business Journal, September 1, 2015